RCMNY
OCUL icon

Rubric Capital Management (New York)’s Ocular Therapeutix OCUL Stock Holding History

Rubric Capital Management (New York)’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-354,728
Closed -$3.55M – 79
2021
Q3 		$3.55M Sell
354,728
-1,801,814
-84% -$20.2M 0.1% 53
2021
Q2 		$30.6M Buy
2,156,542
+1,774,156
+464% +$27M 1.92% 24
2021
Q1 		$6.28M Buy
+382,386
New +$7.36M 0.37% 52

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Rubric Capital Management (New York)'s OCUL Position: Q4 2021 in Review

Rubric Capital Management (New York) sold out of Ocular Therapeutix (OCUL) in Q4 2021, closing a stake of 354,728 shares — an estimated $3.55M sold.

Rubric Capital Management (New York) first reported a position in OCUL in Q1 2021 and held it in 3 quarters. The position peaked at $30.6M in Q2 2021. 140 funds tracked by Wall St. Rank hold OCUL as of Q4 2021.

  • Rubric Capital Management (New York) reported no remaining Ocular Therapeutix position as of Q4 2021 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 354,728 Ocular Therapeutix shares in Q4 2021, an estimated $3.55M.
  • Rubric Capital Management (New York) first reported a position in Ocular Therapeutix in Q1 2021 and held it in 3 quarters.
  • Rubric Capital Management (New York)'s Ocular Therapeutix position peaked at $30.6M in Q2 2021.
  • 140 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2021.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2021, filed 14 Feb 2022.